Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE)
GLIDE_ISO_ARPA-H-SOL-24-111_Final_29_OCT_2024 Program Overview An estimated 10 million Americans are impacted by primary lymphatic diseases, and lymphatic dysfunction contributes to the pathophysiology of many widespread chronic illnesses. Despite the importance of the lymphatic system in disease, there are currently zero FDA-approved treatments, medical devices, or therapies specifically targeting lymphatic growth and function. To catalyze a future […]
Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) Read More »
